FDA Grants Accelerated Approval to AstraZeneca’s Etcamah for ESR1-Mutated Breast Cancer
The Food and Drug Administration granted accelerated approval on September 4 to camizestrant, sold as Etcamah, a new AstraZeneca pill for a subset of patients…
Read More
Center


